SEC Tracker
Get the app
OCUL · XBRL financial data

Ocular Therapeutix financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (OCUL's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers1515*15161517*11131513*1113
Cost of goods and services sold11*1221*1222*12
Research and development1516*21293741*43515251*6654
General and administrative98*14201215*16141618*2022
Operating income (loss)(19)(20)*(32)(44)(46)(51)*(64)(68)(69)(70)*(93)(82)
Interest expense34*4333*3333*33
Other income (expense)0*0*——————————
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(1)(29)*(65)(44)(36)(48)*(64)(68)(69)(65)*(89)(79)
Earnings per share, basic USD per share(0.01)(0.35)*(0.49)(0.26)(0.22)(0.29)*(0.38)(0.39)(0.38)(0.29)*(0.40)(0.35)
Earnings per share, diluted USD per share(0.25)—(0.49)(0.26)(0.22)(0.29)*(0.38)(0.39)(0.38)(0.29)*(0.40)(0.35)
Weighted average shares, basic millions of shares7984*132166167168*169173184223*224225
Weighted average shares, diluted millions of shares85102*132166167168*169173184223*224225

Balance sheet

CSV

Fiscal quarters (OCUL's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents111196483460427392350391345737667599
Accounts receivable242627303032253031312430
Inventory223323333444
Prepaid and other current assets588613131098111112
Total current assets141232520499473441388433387782706644
Property and equipment, net12121111109111017201819
Right-of-use asset766666665566
Total assets162252539517490458406451411808733671
Accounts payable446444566487
Accrued liabilities292916243035313440443639
Total current liabilities353524303641384349514849
Lease liability, non-current776665544343
Total liabilities155161131139138143140145153154151151
Accumulated deficit(668)(698)(762)(806)(843)(891)(955)(1,023)(1,092)(1,157)(1,246)(1,324)
Total stockholders' equity891408378352315266306258654582520
Total liabilities and equity162252539517490458406451411808733671
Common shares outstanding (cover page) millions of shares79149155156157159159174213218219220

Cash flows

CSV

Fiscal quarters (OCUL's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1)(29)*(65)(44)(36)(48)*(64)(68)(69)(65)*(89)(79)
Stock-based compensation5*4*811*7*7*1010*12*11*1615*
Depreciation and amortization1*1*11*1*1*11*1*1*12*
Net cash from operating activities(8)*(22)*(34)(25)*(37)*(39)*(45)(55)*(51)*(54)*(66)(67)*
Purchases of property and equipment0*0*01*0*0*21*6*3*53*
Net cash from investing activities(0)*(0)*(0)(1)*(0)*(0)*(2)(1)*(6)*(3)*(5)(3)*
Proceeds from issuing common stock1*108*3160*————————
Proceeds from long-term debt—year only——————————
Repayments of long-term debt—0*——————————
Net cash from financing activities52*108*3212*4*5*498*10*449*03*
Net change in cash44*85*287(23)*(32)*(35)*(42)41*(46)*392*(70)(68)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Ocular Therapeutix59913(67)*219.6M8.9 quarters 10-QJun 30, 2026
Ligand Pharmaceuticals5679(28)*20.0M— 10-QSep 30, 2026
Sarepta Therapeutics571401197*105.6M— 10-QJun 30, 2026
Supernus Pharmaceuticals1762276.6*58.2M— 10-QSep 30, 2026
Amicus Therapeutics214185*16*314.0M— 10-KDec 31, 2025
Merus36712(85)*75.8M7.5 quarters 10-QSep 30, 2025
Apellis Pharmaceuticals405268(61)128.0M6.6 quarters 10-QMar 31, 2026
Indivior Pharmaceuticals30535697*118.0M— 10-QSep 30, 2026
Arrowhead Pharmaceuticals5575(177)*141.3M9.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.